Chronic pain-induced depression: how ketamine acts as an antidepressant

I Use Ketamine for Depression - Here's How It Works - YouTube

Chronic pain often leads to depression, which increases suffering and is clinically challenging to treat. Now, for the first time, researchers have uncovered the underlying mechanism that drives those depressive systems, according to a study published in The Journal of Clinical Investigation.

The mechanism acts to cause hypersensitivity in a part of the brain called the anterior cingulate cortex, or ACC, and knowledge of this mechanism identifies a potential therapeutic target for the treatment of chronic pain-induced depression, say Lingyong Li, Ph.D., and Kimberley Tolias, Ph.D., co-leaders of the research.

“Chronic pain is a major, unmet health issue that impacts the quality of life,” said Li, an associate professor at the University of Alabama at Birmingham Department of Anesthesiology and Perioperative Medicine. “Unfortunately, patients suffering from chronic pain have limited effective treatment options.”


The research focused on a protein called Tiam1, which modulates the activity of other proteins that help build or unbuild the cytoskeletons of cells. Specifically, the research teams of Li and Tolias, a professor at Baylor College of Medicine, Houston, Texas, found that chronic pain in a mouse model leads to an activated Tiam1 in ACC pyramidal neurons, resulting in an increased number of spines on the neural dendrites. Dendrites are tree-like appendages attached to the body of a neuron that receive communications from other neurons.

This higher spine density increased the number of connections and the strength of those connections between neurons, a change known as synaptic plasticity. Those increases caused hypersensitivity and were associated with depression in the mouse model. Reversing the number and strength of connections in the model by using an antagonist of Tiam1, relieved the mice of depression and diminished hypersensitivity of the neurons.

The ACC was already known as a critical hub for comorbid depressive symptoms in the brain. To investigate the mechanism for those symptoms, the team led by Li and Tolias first showed that Tiam1 in the ACC was activated in two mouse models of chronic pain with depressive or anxiety-like behaviours compared to controls.

To show that Tiam1 in the ACC modulates chronic pain-induced depressive-like behaviors, the researchers used molecular scissors to delete Tiam1 from the forebrain excitatory neurons of the mice. These mice were viable and fertile and displayed no gross alterations, and they still showed hypersensitivity to chronic pain. Strikingly, however, these Tiam1 conditional knockout mice did not display depressive- or anxiety-like behaviors in five tests that gauge depression or anxiety.

When researchers specifically deleted Tiam1 from ACC neurons, they found the same results as the broader forebrain deletion. Thus, Tiam1 expressed in ACC neurons specifically mediates chronic pain-induced depressive-like behaviors.

Other studies have established that an underlying cause of stress-induced depression and anxiety disorders is alterations in synaptic connections in brain regions involved in mood regulation, including the prefrontal cortex, the hippocampus and the amygdala. Li and Tolias found similar changes in dendritic neurons in the ACC for chronic pain-induced depressive-like behavior — they saw a significant increase in dendritic spine density and signs of increased cytoskeleton building. This was accompanied by increased NMDA receptor proteins and increased amplitudes of NMDA currents in the ACC neurons, both associated with hyperactivity.

These maladaptive changes were not seen in the Tiam1-knockout mice.

Researchers further showed that inhibiting Tiam1 signaling with a known inhibitor alleviated the chronic pain-induced depressive-like behaviors, without reducing the chronic pain hypersensitivity itself. The inhibition also normalized dendritic spine density, cytoskeleton building, NMDA receptor protein levels and NMDA current amplitudes.

Ketamine is a drug known to produce rapid and sustained antidepressant-like effects in chronic pain-induced depression, without decreasing sensory hypersensitivity. However, its mechanism is not fully understood. Li, Tolias and colleagues showed that ketamine’s sustained antidepressant-like effects in chronic pain are mediated, at least in part, by ketamine’s blocking the Tiam1-dependent, maladaptive synaptic plasticity in the mouse ACC neurons.

“Our work demonstrates the critical role Tiam1 plays in the pathophysiology of chronic pain-induced mood dysregulation and the sustained antidepressant-like effects of ketamine, revealing it as a potential therapeutic target for the treatment of comorbid mood disorders in chronic pain,” Li said.

5-MINUTE MEDITATION FOR CHRONIC PAIN – Meditation for chronic pain management – Beginner friendly

5 MINUTE MEDITATION FOR CHRONIC PAIN - Meditation for chronic pain  management - Beginner friendly - YouTube


I hope you enjoy this 5-minute meditation for chronic pain. This guided meditation is designed to help you with chronic pain management and relief. Meditation is a beautiful, holistic way to help with chronic pain and fibromyalgia, as it works on the mind, body, and soul! Meditation can help the body and mind to relax. This meditation practice is beginner friendly and can be done sitting or lying down. Did you know that meditation is part of yoga? So if you’re meditating, you’re practising yoga!




Chronic pain management program delivered by ‘coaches’ improves outcomes

Paula Redpath


Flinders University Behavioural Health expert Paula Redpath, from the College of Medicine and Public HealthCREDIT Flinders University

Chronic pain affects millions of people worldwide and is a leading cause of disability and healthcare use.

A new study led by Flinders University has shown that timely, affordable, integrated and individualised ‘coaching’ can help people living with chronic pain to improve their self-management and understanding of ways to manage their pain better.

A novel telehealth program developed by Flinders University and SA Health experts shows the potential for non-mental health professionals – in tandem with medical and allied health experts – to help those with chronic pain access specialised support that can make a difference and reduce suffering.

The program also provides access to care and support for people living outside of metro areas who may have to wait years otherwise to see a pain specialist, says Flinders University Behavioural Health expert Paula Redpath, from the College of Medicine and Public Health.

A pilot study of the ‘Rethinking Pain’ guided self-help program in South Australia showed it to be a promising model for providing specialised information and support through supervised ‘coaches’ who worked with people with chronic pain to increase their understanding of their condition and improve their self-management. 

“Accessing care and support for chronic pain is difficult, time-consuming and costly, particularly for people living in rural and remote areas,” says Ms Redpath, Behavioural Health Discipline Lead at Flinders University.

“Chronic pain is a complex condition that requires specialised, multidisciplinary teams to provide effective and integrated care.

“Once a person understands helpful ways to manage their chronic pain, they can choose what strategies they want to use to self-manage.

“The coaches guide and assist people with these strategies, which they can then take away and use.”

The program can be offered via telehealth or in person and involves goal setting, pain conceptualisation, activity scheduling, psycho-education, pacing and cognitive strategies, with the evaluation of the program outcomes demonstrating significant improvement in patients’ reported independence and quality of life.

“Coaches can become part of the multidisciplinary team and support patients by providing information and strategies to manage their chronic pain. This can relieve pressure on higher-trained health and medical professionals, allowing them to concentrate on more complex care,” says Flinders University academic Dr Peter Herriot from the SA Health Southern Adelaide Local Health Network (SALHN) Pain Management Unit, who supervised the trial.

“This evidence-based program has the potential to not only improve access to care for people who are living with chronic pain but also to be scaled up and adopted across various healthcare settings.”

The guided self-help (GSH) program, developed by Flinders University experts, was delivered by supervised postgraduate students from the University’s Master of Cognitive Behaviour Therapy course who undertook a placement at SA Health’s Pain Management Unit at Flinders Medical Centre, Bedford Park.

An estimated 1 in 5 Australians aged 45 and over have chronic pain. The annual direct and indirect costs of chronic pain is estimated at $139 billion, including loss of productivity and quality of life.

Wider implementation of programs such as ‘Rethinking Pain’ is essential to expand and improve care options for people with chronic pain, adds Ms Redpath.

“Disseminating this specialist knowledge to a diversified health workforce and peers in the community and through primary care services may also reduce demand for psychiatrists and psychologists whose services are limited and hard to access.”

People living with chronic pain can also experience significant physical and emotional impacts, including on sleep quality and well-being as well as impacts on employment. Access to adequate support services can be difficult due to social disadvantages.

The availability of recreational cannabis reduced the demand for prescription codeine. Have you used cannabis for pain? Tell us more in the comments!


States that permit the recreational use of cannabis to see a reduction in demand for prescription codeine, an opioid with a high potential for misuse, according to a new multi-institutional study led by University of Pittsburgh and Cornell University scientists.

Published this week in Health Economics, the study finds a significant reduction in pharmacy-based codeine distribution in states that have legalized recreational cannabis use. The finding is promising from a public health policy perspective because misuse of prescription opioids annually contributes to more than 10,000 overdose deaths.

Twenty-one U.S. states have passed recreational cannabis laws, and legislatures in other states are considering similar measures.

“A reduction in the misuse of opioids can save lives,” said lead author Shyam Raman, a doctoral candidate in Cornell’s Jeb E. Brooks School of Public Policy. “Our research indicates that recreational cannabis laws substantially reduce the distribution of codeine to pharmacies, an overlooked potential benefit to legalizing recreational cannabis use.”

The study is among the first to examine the impact of recreational cannabis laws on shipments of opioids to hospitals, pharmacies and other endpoint distributors. Previous studies have focused on medical cannabis laws or the use of opioids by subsets of consumers, such as Medicaid beneficiaries.

The researchers analyzed data from the Drug Enforcement Administration’s Automation of Reports and Consolidation Orders System (ARCOS) which tracks the flow of controlled substances in the U.S. These are their key findings from states that passed recreational cannabis laws:

  • A reduction of 26% in the pharmacy-based distribution of codeine and as much as a 37% reduction after recreational cannabis laws have been in effect for four years.
  • Minimal impact on the distribution of other opioids such as oxycodone, hydrocodone and morphine in any setting.
  • Minimal impact on codeine distribution by hospitals which often have less permissive policies than pharmacies.

“This finding is particularly meaningful,” said senior author Coleman Drake, Ph.D., assistant professor of health policy and management at Pitt’s School of Public Health. “Among prescription opioids, codeine misuse is especially high. Our findings suggest recreational cannabis use may be a substitute for codeine misuse.”

While cannabis and opioids can be used to minimize chronic pain symptoms, they aren’t equivalent in their impact on health.  

“Increasing legal access to cannabis may shift some consumers away from opioids and towards cannabis,” said Johanna Catherine Maclean, Ph.D., of George Mason University. “While all substances have some risks, cannabis use is arguably less harmful to health than the non-medical use of prescription opioids.”

Study reveals mechanism involved in neuropathic pain and could help develop specific treatment

Neuropathic pain is chronic and caused by injury to the nervous system, affecting between 3% and 15% of the population. The only treatment options currently available are drugs initially developed for other conditions, such as epilepsy or depression

Isochronic music to help ease chronic pain, headaches, or sleep.


Neuropathic pain is a type of chronic pain caused by damage to the nervous system due mainly to metabolic diseases such as diabetes and arthritis, or to the side effects of some kinds of chemotherapy. It is believed to affect between 3% and 15% of the population, depending on the country, but specific medications are not yet available. The drugs currently in use were originally designed for the treatment of other conditions, such as epilepsy or depression.

Now, however, after a decade of research, a group of Brazilian scientists has succeeded in describing a mechanism associated with the production of neuropathic pain, opening up a new stage of their exploration in search of drugs that can act on the metabolic pathway in question and pointing to an avenue for the development of targeted therapies.

The study revealed the role played in neuropathic pain by dendritic cells present in the meninges, the membranes that cover the central nervous system, via an increase in the metabolic kynurenine pathway.

This pathway is responsible for the amino acid metabolism essential to the production of vitamin B3 (tryptophan) and performs important functions in various physiological processes, such as immune response organization. Previous research had already detected a link between increased production of kynurenine and the development of depression and other psychiatric disorders, for example.

In this study, the scientists found that neuropathic pain was nullified when the kynurenine pathway initiated by the enzyme IDO1 (indoleamine 2,3-dioxygenase 1) was blocked pharmaceutically or genetically. An article reporting the results is published in the Journal of Clinical Investigation.

“It was a very lengthy study because we wanted to explore in depth all the mechanisms that could be involved. It required collaboration in Brazil and abroad with leading experts, such as Andrew Mellor [a professor at Augusta University, formerly Georgia Regents, in the United States], one of the world’s foremost specialists in IDO. The results we obtained offer the prospect of developing novel compounds to block this pathway. We believe inhibitors of the pathway could play a key role in controlling neuropathic pain,” Thiago Mattar Cunha, last author of the article, told Agência FAPESP. Mattar Cunha is a professor at the University of São Paulo’s Ribeirão Preto Medical School (FMRP-USP).

Inflammation

Previous research had already shown that the kynurenine pathway, whose formation depends on several enzymes but primarily on IDO1, is involved in pain. Because IDO1 is induced during pathological processes, especially inflammation, by pro-inflammatory cytokines, the researchers hypothesized that the neuroinflammation that causes neuropathic pain could increase IDO, raising the levels of these neurotoxic or neurostimulatory metabolites.

“We used various tools to prove and elucidate the role played by these enzymes and other products in neuropathic pain,” Mattar Cunha said. “We used mice as a model and showed that neuropathic pain decreased in animals with a deficiency of these enzymes, or with the enzymes inhibited. We then set out to understand the mechanism.”

In the article, the researchers explain that they used “a well-established model of peripheral nerve injury-induced neuropathic pain”, known as the spared nerve injury model, and activation of spinal cord microglial cells (a type of central nervous system cell involved in the immune response). In the spinal cord, kynurenine was metabolized by astrocytes, and the glutamatergic receptor was activated.

“We showed for the first time that when peripheral nerves are injured, immune cells infiltrate the meninges that protect the spinal cord and dorsal root ganglion, producing mediators which cause or maintain pain hypersensitivity. IDO1 and its metabolites are produced in this process. We showed that these metabolites come mainly from dendritic cells in the meninges, causing hypersensitivity and amplifying the glutamatergic pathway, whose receptors play an important role in chronic pain,” Mattar Cunha said.

Although the study used pain models involving physical nerve injury, he added, the mechanism is similar in other neuropathic conditions, such as infectious diseases caused by HIV and other viruses.